Idoxuridine

CHEMBL788 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
354.1 g/mol
LogP
-1.0
Phase
4

This antiviral drug works by incorporating into viral DNA in place of thymidine, disrupting replication of DNA viruses such as herpes simplex. It is used topically as eye drops to treat herpes simplex keratitis (viral eye infection) and as a skin cream for herpes labialis. It is too toxic for systemic use and is limited to topical applications.

Peso molecular

354,1000 g/mol

LogP

-1,00

TPSA

99,10 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I

InChI

InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1

Molecular Formula

C9H11IN2O5

HBD / HBA

3 / 5

Enlaces Rotables

2

Átomos Pesados

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This antiviral drug works by incorporating into viral DNA in place of thymidine, disrupting replication of DNA viruses such as herpes simplex. It is used topically as eye drops to treat herpes simplex keratitis (viral eye infection) and as a skin cream for herpes labialis. It is too toxic for systemic use and is limited to topical applications.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Idoxuridine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL788. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5905. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.